Pharma BD Deal Intelligence

Mirador Therapeutics, Inc. / Kira Pharmaceuticals

2026 · Licensing/Option · $12M · Complete

The coverage arc

Jul 16, 2026 biospace.com Bullish

Mirador Therapeutics enters an exclusive worldwide license to KP-301, a long-acting anti-C5a antibody with potential in ANCA-associated vasculitis; Phase…

Jul 16, 2026 globenewswire.com Neutral

Kira out-licenses KP-301 (anti-C5a mAb) and KP-402 (C5a receptor antagonist) to Mirador Therapeutics for $12M upfront plus development and sales milestones.

Source summaries from our enrichment pipeline; follow links for originals.

All 3 sources with sentiment breakdown →

Mirador Therapeutics entered an exclusive worldwide license agreement with Kira Pharmaceuticals for KP-301, a long-acting anti-C5a monoclonal antibody, and KP-402, a small-molecule C5a receptor antagonist, announced July 16, 2026 alongside Kira's acquisition by Jasper Therapeutics. Mirador pays $12 million upfront plus undisclosed development and sales milestones. KP-301 is targeted at ANCA-associated vasculitis, with a Phase 1 study planned by year-end 2026 and a Phase 2 AAV study in H1 2027, with potential expansion into additional inflammatory indications.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2026 deals